Dr. Jack Jacobs obtained his Ph.D. in Molecular Biology from the Washington University School of Medicine in St. Louis, where he conducted research in Ralph Bradshaw, PhD's lab, which pioneered the isolation and characterization of the growth factor, FGF-1. Following graduation, he ventured into Merck & Co., establishing the Department of Biological Chemistry and contributing to Merck's scientific leadership.

Later, he transitioned to CardioVascular BioTherapeutics as their Chief Scientific Officer, collaborating with Daniel Montano. Under his supervision, FDA-authorized clinical trials explored the applications of human FGF-1 across various medical conditions, including coronary artery disease and diabetic foot ulcers. Dr. Jacobs managed the manufacturing processes of FGF-1 for these clinical studies.

Presently, with Zhittya Genesis Medicine, Dr. Jacobs persists in advancing the clinical development of human FGF-1 for diverse medical indications. His focus extends to neurodegenerative diseases such as Parkinson's disease and ALS (motor neuron disease).